9 unchanged sentences
The historical stock price performance of our Common Stock shown in the graph below is not necessarily indicative of future stock price performance.
+Added: 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020
+Added: Regeneron $ 100.00 $ 67.62 $ 69.25 $ 68.80 $ 69.17 $ 88.99
+Added: S&P 500 $ 100.00 $ 109.54 $ 130.81 $ 122.65 $ 158.07 $ 183.77
NQ US Pharma TR Index $ 100.00 $ 98.91 $ 119.09 $ 127.20 $ 145.65 $ 160.97
1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock awards or restricted stock units granted under one of our long-term incentive plans, during the fourth quarter of 2019.
+Added: The table below reflects shares of Common Stock we repurchased under the share repurchase program approved in November 2019, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended December 31, 2020.
Refer to Part II, Item 7.
"Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources - Share Repurchase Program " for further details of the share repurchase program.
−Removed: Total Number of Shares Purchased
−Removed: Average Price Paid per Share
−Removed: Total Number of Shares Purchased as Part of a Publicly Announced Program
−Removed: Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
+Added: Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of a Publicly Announced Program Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program (b)
10/1/2020–10/31/2020 72,870 $ 556.23 72,870 $ 332,144,883
11/1/2020–11/30/2020 596,867 $ 524.36 596,867 $ 19,172,999
−Removed: (a) The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program is related to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock awards or restricted stock units granted under one of our long-term incentive plans.
+Added: 12/1/2020–12/31/2020 41,636 $ 516.76 36,854 —
+Added: Total 711,373 (a)
+Added: (a) The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program relates to Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans.
+Added: (b) In January 2021, our board of directors authorized a new share repurchase program to repurchase up to $1.5 billion of our Common Stock.
+Added: "Liquidity and Capital Resources - Share Repurchase Program" for further details.
SELECTED FINANCIAL DATA
The selected financial data set forth below for the years ended December 31, 2020, 2019, and 2018 and as of December 31, 2020 and 2019 are derived from and should be read in conjunction with our audited financial statements, including the notes thereto, included elsewhere in this report.
−Removed: The selected financial data for the years ended December 31, 2016 and 2015 and as of December 31, 2017 , 2016 , and 2015 are derived from our audited financial statements not included in this report.
−Removed: Certain prior year amounts have been reclassified to conform to the current year's presentation.
+Added: Certain prior year amounts have been reclassified to conform to the current year's presentation, including revisions related to the change in presentation for certain amounts received from collaborators who are not deemed to be our customers;
+Added: see Note 1 to our Consolidated Financial Statements for further details.
Year Ended December 31,
4 unchanged sentences
Other revenue 557.0 174.0 129.0 82.7 68.3
+Added: 8,497.1 6,557.6 5,145.6 4,257.5 3,630.6
Research and development (1)
+Added: 2,735.0 2,450.0 1,468.8 1,180.5 1,297.4
Selling, general, and administrative 1,346.0 1,341.9 1,127.2 940.0 860.9
1 unchanged sentence
Cost of collaboration and contract manufacturing 628.0 402.8 237.5 169.4 82.6
+Added: Other operating (income) expense, net (280.4) (209.2) (402.3) (314.5) (135.6)
+Added: 4,920.5 4,347.8 2,611.2 2,177.9 2,299.9
Income from operations 3,576.6 2,209.8 2,534.4 2,079.6 1,330.7
2 unchanged sentences
Income tax expense (2)
+Added: 297.2 313.3 109.1 880.0 434.3
+Added: Net income $ 3,513.2 $ 2,115.8 $ 2,444.4 $ 1,198.5 $ 895.5
Net income per share - basic $ 32.65 $ 19.38 $ 22.65 $ 11.27 $ 8.55
4 unchanged sentences
Cash, cash equivalents, and marketable securities (current and non-current)
+Added: $ 6,722.6 $ 6,471.1 $ 4,564.9 $ 2,896.0 $ 1,902.9
+Added: Total assets $ 17,163.3 $ 14,805.2 $ 11,734.5 $ 8,764.3 $ 6,973.5
+Added: Long-term debt (3)
+Added: $ 1,978.5 — — — —
Finance lease liabilities
+Added: $ 717.2 $ 713.9 $ 708.5 $ 703.5 $ 481.1
Stockholders' equity $ 11,025.3 $ 11,089.7 $ 8,757.3 $ 6,144.1 $ 4,449.2
1 unchanged sentence
See Part I, Item 1.
−Removed: "Collaboration Agreements - Collaboration with Alnylam ") for further details.
−Removed: (2) Income taxes for the year ended December 31, 2018 includes a $162.1 million income tax benefit related to the Company's sale of non-inventory related assets between foreign subsidiaries.
+Added: "Collaboration, License, and Other Agreements - Alnylam") for further details.
(2) As a result of the Tax Cuts and Jobs Act being signed into law in December 2017, income taxes for the year ended December 31, 2017 included a charge of $326.2 million related to the re-measurement of our U.S.
1 unchanged sentence
See Note 14 to our Consolidated Financial Statements for further details.
+Added: (3) In 2020, the Company issued and sold senior unsecured notes.
+Added: "Liquidity and Capital Resources - Issuance of Senior Notes" for further details.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.